Announcing Expansion for Enhanced Capabilities

U.S. CDMO Capacity

More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand

Pharma's Almanac

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Tariffs

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Partnerships

What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?

Pharma's Almanac

CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

Risk Sharing

Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal

David Alvaro, Ph.D.

Pharma's Almanac

Partnerships

Structured Deals on the Rise: Milestones, Options, and Risk-Sharing in Biopharma Licensing

David Alvaro, Ph.D.

Pharma's Almanac

Big Science

The Economics of Big Science — and Why It Matters for Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Biotech Funding

Selective Capital, Stronger Science: The Emerging Biotech Funding Model

David Alvaro, Ph.D.

Pharma's Almanac